R K Portenoy
Overview
Explore the profile of R K Portenoy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
5874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M, et al.
J Clin Oncol
. 2023 Dec;
41(36):5482-5492.
PMID: 38100992
Purpose: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the...
2.
Portenoy R
J Back Musculoskelet Rehabil
. 2014 Feb;
3(2):44-52.
PMID: 24573025
Back pain is a common symptom in the cancer population. For some patients, the complaint reflects a process independent of the underlying disease, such as myofascial pain, discogenic disease, or...
3.
Cherny N, Portenoy R
J Back Musculoskelet Rehabil
. 2014 Feb;
3(2):7-26.
PMID: 24573022
Chronic pain is experienced by approximately one-third of all cancer patients and as many as 70 to 90% of those with advanced disease.1 Although established pharmacotherapeutic strategies have been demonstrated...
4.
von Gunten C, Sloan P, Portenoy R, Schonwetter R
J Palliat Med
. 2005 Apr;
3(4):441-7.
PMID: 15859696
The American Board of Hospice and Palliative Medicine (ABHPM) was formed in 1995 to establish and implement standards for certification of physicians practicing hospice and palliative medicine and, ultimately, accreditation...
5.
Cleeland C, Portenoy R, Rue M, Mendoza T, Weller E, Payne R, et al.
Ann Oncol
. 2005 Apr;
16(6):972-80.
PMID: 15821119
Background: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology...
6.
Lesage P, Portenoy R
Pain Med
. 2004 Apr;
2(2):121-30.
PMID: 15102301
The approach to management of patients with advanced disease and serious illness has been strongly influenced by advances in science and technology, the increasing role of ethics in clinical practice,...
7.
Farrar J, Portenoy R
Oncology (Williston Park)
. 2002 Jan;
15(11):1435-42, 1445; discussion 1445, 1450-3.
PMID: 11758872
Neuropathic pain may be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. This pathophysiologic label is typically applied when the painful symptom...
8.
Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, et al.
J Pain Symptom Manage
. 2001 Aug;
22(1):575-83.
PMID: 11516599
This open-label study evaluated the long-term safety and tolerability of oral transmucosal fentanyl citrate (OTFC) in ambulatory cancer patients with breakthrough pain undergoing cancer care at 32 university- or community-based...
9.
Mercadante S, Portenoy R
J Pain Symptom Manage
. 2001 Apr;
21(4):338-54.
PMID: 11312049
Some pain syndromes may be difficult to treat due to a poor response to opioids. This situation demands a range of alternative measures, including the use of adjuvant drugs with...
10.
Coluzzi P, Schwartzberg L, CONROY J, Charapata S, Gay M, Busch M, et al.
Pain
. 2001 Mar;
91(1-2):123-30.
PMID: 11240084
Oral transmucosal fentanyl citrate (OTFC); Actiq) is a drug delivery formulation used for management of breakthrough cancer pain. Previous studies with open-label comparisons indicated OTFC was more effective than patients'...